Canagliflozin

Last updated

Canagliflozin
Canagliflozin structure.svg
Clinical data
Pronunciation /ˌkænəɡlɪˈfloʊzɪn/ KAN-ə-glif-LOH-zin
Trade names Invokana, Sulisent, Prominad, others
Other namesJNJ-28431754; TA-7284; (1S)-1,5-anhydro-1-C-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl]}-4-methylphenyl)-D-glucitol
AHFS/Drugs.com Monograph
MedlinePlus a613033
License data
Pregnancy
category
Routes of
administration 		By mouth (tablets)
Drug class SGLT2 inhibitor
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU:Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 65%
Protein binding 99%
Metabolism Liver glucuronidation
Elimination half-life 11.8 (10–13) hours
Excretion 53% faecal and 33% kidney
Identifiers
  • (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.223.671 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C24H25FO5S
Molar mass 444.52 g·mol−1
3D model (JSmol)
Melting point 98 °C (208 °F)
  • Cc1ccc(cc1Cc2ccc(s2)c3ccc(cc3)F)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
  • InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1 X mark.svgN
  • Key:XTNGUQKDFGDXSJ-ZXGKGEBGSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. [2] It is used together with exercise and diet. [2] It is not recommended in type 1 diabetes. [2] It is taken by mouth. [2]

Contents

Common side effects include vaginal yeast infections, nausea, constipation, and urinary tract infections. [2] Serious side effects may include low blood sugar, Fournier's gangrene, leg amputation, kidney problems, high blood potassium, and low blood pressure. [2] Diabetic ketoacidosis may occur despite nearly normal blood sugar levels. [2] Use in pregnancy and breastfeeding is not recommended. [1] Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. [2] It works by increasing the amount of glucose lost in the urine. [2]

Canagliflozin was approved for medical use in the United States, in the European Union, and in Australia in 2013. [2] [3] [4] [5] It is on the World Health Organization's List of Essential Medicines. [6]

Medical uses

Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for heart failure in certain people with type 2 diabetes and diabetic kidney disease. [7]

Canagliflozin is an anti-diabetic medication used to improve blood sugar control in people with type 2 diabetes. It is a third-line medication to metformin. [8] Per the British National Formulary it is also less preferred than a sulfonylurea as of 2019, while the American Diabetes Association and European Association for the Study of Diabetes consider either a SGLT2 inhibitor or GLP-1 receptor agonist a reasonable second line medication in those with heart disease. [9]

Canagliflozin decreases HbA1c levels by 0.77% to 1.16% when given by itself, in combination with metformin, in combination with metformin and a sulfonylurea, in combination with metformin and pioglitazone, or in combination with insulin, from initial HbA1c levels of 7.8% to 8.1%. When added to metformin, canagliflozin does not appear worse than sitagliptin or glimepiride in reducing HbA1c levels, while canagliflozin maybe better than sitagliptin and glimiperide in decreasing HbA1c. It is unclear whether or not it has any unique cardiovascular benefits beyond lowering blood sugar. [10] Although canagliflozin produces beneficial effects on HDL cholesterol, it has also been shown to increase LDL cholesterol to produce no change in total cholesterol. [11] [12]

Evidence shows that apart from positive effects on glycemic levels, canagliflozin also reduces the risk of heart attacks and heart failures. [13]

SGLT2 inhibitors, including canagliflozin, reduce the likelihood of hospitalization for congestive heart failure or progression of renal disease in persons with diabetes mellitus type 2 and reduce the likelihood of stroke and heart attack in persons with diabetes mellitus type 2 who have known atherosclerotic vascular disease. [14]

Contraindications

Canaglifozin is contraindicated in:

Adverse effects

As with other SGLT2 inhibitors, canagliflozin is associated with increased incidence of urinary tract infections, fungal infections of the genital area, thirst, [17] elevations in LDL cholesterol, increased urination and episodes of low blood pressure. Rarely, use of canagliflozin is associated with necrotizing fasciitis of the perineum, also called Fournier gangrene. [18] There are concerns that it may also increase the risk of diabetic ketoacidosis. [19]

Possible cardiovascular problems are an ongoing issue with gliflozin drugs. [20] The pre-specified endpoint for cardiovascular safety in the canagliflozin clinical development program was "Major Cardiovascular Events Plus", defined as the occurrence of cardiovascular death, non-fatal myocardial infarctions, non-fatal strokes, or unstable angina leading to hospitalization. This endpoint occurred in more people in the placebo group (20.5%) than in the canagliflozin treated group (18.9%).

Nonetheless, a United States Food and Drug Administration (FDA) advisory committee expressed concern regarding the cardiovascular safety of canagliflozin. A greater number of cardiovascular events was observed during the first 30 days in study subjects who received canagliflozin (0.45%) compared those who received placebo (0.07%), suggesting an early period of increased cardiovascular risk. In addition, there was an increased risk of stroke in subjects who received canagliflozin. However, none of these effects were statistically significant. Additional cardiovascular safety data from another ongoing study are expected in 2015. [20]

On 15 May 2015, the FDA issued a warning that certain SGLT2 diabetes drugs, including canagliflozin, may lead to ketoacidosis, a condition where the body produces higher levels of ketone bodies. The FDA is continuing to investigate the issue, and cautions that patients should not stop taking canagliflozin without first talking to their doctor. [21]

On 10 September 2015, the FDA issued a drug safety communication for canagliflozin to address risks for bone fracture and decreased bone density. A label warning for fractures was already included in the Adverse Reactions section; however, the FDA made the addition to the Warnings and Precautions section to reflect new information from a placebo study. They advised that health care professionals should consider fracture risk factors before prescribing canagliflozin, and patients should disclose any bone fracture risk factors to their doctors, but that patients should not stop taking the medication without first talking to their doctor. [22]

On 4 December 2015, the FDA issued another safety communication for SGLT2 inhibitors, indicating that it would require new warnings to be added to the canagliflozin label about elevated blood acid levels and urinary tract infections. [23]

In June 2016, the FDA strengthened the warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). [24]

A 29 June 2016, report on the ongoing cardiovascular outcomes trial for canagliflozin (CANVAS) revealed interim findings of new safety concerns including heightened risk of bone fracture that was found to increase with the duration of treatment. [25]

In May 2016, the FDA announced they were going to investigate a safety issue related to clinical trials that found an increase in leg and foot amputations, mostly affecting the toes, in people treated with the diabetes medicine canagliflozin (Invokana, Invokamet). [26] In May 2017, the FDA concluded that canagliflozin causes an increased risk of leg and foot amputations. [27] The FDA began requiring a boxed warning to be added to the canagliflozin drug labels to describe this risk. [28] In August 2020, the FDA removed the requirement for the boxed warning. [7]

To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery. [29]

Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing. [29]

Interactions

The drug may increase the risk of dehydration in combination with diuretic drugs. [30]

Because it increases renal excretion of glucose, treatment with canagliflozin prevents renal reabsorption of 1,5-anhydroglucitol, leading to artifactual decreases in serum 1,5-anhydroglucitol. Therefore, canagliflozin can interfere with the use of serum 1,5-anhydroglucitol (assay trade name, GlycoMark) as a measure of postprandial glucose levels. [31]

Dosing adjustment is also required for concomitant therapy with UDP-glucuronosyl transferase (UGT) inducers such as rifampin, phenytoin, or phenobarbital, ritonavir. [2]

Pharmacology

Mechanism of action

Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (the remaining 10% is done by SGLT1 inhibition [32] [33] ). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine, [34] corresponding to 476 kilocalories. Additional water is eliminated by osmotic diuresis, resulting in a lowering of blood pressure.

This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to other types of anti-diabetic drugs such as sulfonylurea derivatives and insulin. [35]

Pharmacokinetics

When taken by mouth, canagliflozin reaches highest blood plasma concentrations after one to two hours and has an absolute bioavailability of 65%, independently of food intake. When in the bloodstream, 99% of the substance are bound to plasma proteins, mainly albumin. It is metabolized mainly by O-glucuronidation via the enzymes UGT1A9 and UGT2B4, and by hydroxylation to a lesser extent. The terminal half life is 10.6 hours for a 100 mg dose and 13.1 hours for a 300 mg dose, with 43% being excreted in the faeces (mostly in unchanged form) and 33% in the urine (mostly as glucuronide). [36]

History

It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. [37]

On 4 July 2011, the European Medicines Agency (EMA) approved a paediatric investigation plan and granted both a deferral and a waiver for canagliflozin (EMEA-001030-PIP01-10) in accordance with EC Regulation No.1901/2006 of the European Parliament and of the council. [38] It was approved for medical use in the European Union in November 2013. [4]

Canagliflozin was approved by the FDA on 29 March 2013, and became the first SGLT2 inhibitor in the United States. [3] [39]

Canagliflozin was approved for medical use in Australia in September 2013. [5]

See also

Related Research Articles

<span class="mw-page-title-main">Metformin</span> Medication used to treat diabetes by reducing glucose levels

Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. It is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotics. Metformin is not associated with weight gain and is taken by mouth.

Drugs used in diabetes treat diabetes mellitus by decreasing the glucose level in the blood. With the exception of insulin, most GLP receptor agonists, and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of hypoglycemic drugs, and their selection depends on the nature of diabetes, age, and situation of the person, as well as other factors.

<span class="mw-page-title-main">Dipeptidyl peptidase-4 inhibitor</span> Enzyme blocker and diabetes treatment drug

Inhibitors of dipeptidyl peptidase 4 are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2.

<span class="mw-page-title-main">Sitagliptin</span> Diabetes medication

Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also available in the fixed-dose combination medication sitagliptin/metformin.

Sodium-dependent glucose cotransporters are a family of glucose transporter found in the intestinal mucosa (enterocytes) of the small intestine (SGLT1) and the proximal tubule of the nephron. They contribute to renal glucose reabsorption. In the kidneys, 100% of the filtered glucose in the glomerulus has to be reabsorbed along the nephron. If the plasma glucose concentration is too high (hyperglycemia), glucose passes into the urine (glucosuria) because SGLT are saturated with the filtered glucose.

<span class="mw-page-title-main">Saxagliptin</span> Chemical compound

Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.

<span class="mw-page-title-main">Sodium/glucose cotransporter 2</span> Protein-coding gene in the species Homo sapiens

The sodium/glucose cotransporter 2 (SGLT2) is a protein that in humans is encoded by the SLC5A2 gene.

<span class="mw-page-title-main">Dapagliflozin</span> Diabetes medication

Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease.

<span class="mw-page-title-main">Alogliptin</span> Chemical compound

Alogliptin, sold under the brand names Nesina and Vipidia,) is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.

<span class="mw-page-title-main">Remogliflozin etabonate</span> Chemical compound

Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina, US-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with BHV. In 2002, GlaxoSmithKline (GSK) received a license to use it. From 2002 to 2009, GSK carried out a significant clinical development program for the treatment of type-2 diabetes mellitus in various nations across the world and obesity in the UK. Remogliflozin etabonate's pharmacokinetics, pharmacodynamics, and clinical dose regimens were characterized in 18 Phase I and 2 Phase II investigations. Due to financial concerns, GSK stopped working on remogliflozin and sergliflozin, two further SGLT2 inhibitors that were licensed to the company, in 2009. Remogliflozin was commercially launched first in India by Glenmark in May 2019.

Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. It is not recommended for type 1 diabetes. It is taken by mouth.

<span class="mw-page-title-main">Dulaglutide</span> Diabetes medication

Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.

Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria. The mechanism of action is insulin independent.

SGLT2 inhibitors, also called gliflozins or flozins, are a class of medications that inhibit sodium-glucose transport proteins in the nephron, unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. As of 2014, several medications of this class had been approved or were under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.

<span class="mw-page-title-main">Ertugliflozin</span> Chemical compound

Ertugliflozin, sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes.

Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure.

Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a drug combination used for the treatment of type 2 diabetes. It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.

Dapagliflozin/metformin, sold under the brand name Xigduo XR amongst others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and metformin and is taken by mouth.. Dapagliflozin/metformin was approved for use in the European Union in January 2014, in the United States in February 2014, and in Australia in July 2014.


Dapagliflozin/Saxagliptin is a combination medication designed to help manage diabetes mellitus, a chronic condition that affects how the body handles glucose (sugar). This medication combines two active ingredients, dapagliflozin/Saxagliptin, to address different aspects of diabetes control. Dapagliflozin/Saxagliptin sold under the brand name Qtern. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth.

Canagliflozin/metformin, sold under the brand name Vokanamet among others, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes. It is used in combination with diet and exercise. It is taken by mouth.

References

  1. 1 2 "Canagliflozin (Invokana) Use During Pregnancy". Drugs.com. Retrieved 6 April 2019.
  2. 1 2 3 4 5 6 7 8 9 10 11 "Canagliflozin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.
  3. 1 2 "Drug Approval Package: Invokana (canagliflozin) Tablets NDA #204042". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 28 August 2020.
  4. 1 2 "Invokana EPAR". European Medicines Agency (EMA). Retrieved 29 August 2020.
  5. 1 2 "Australian Public Assessment Report for Canagliflozin (as hemihydrate)" (PDF). Therapeutic Goods Administration (TGA). 31 March 2014. Retrieved 28 August 2020.
  6. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  7. 1 2 "FDA removes Boxed Warning for type 2 diabetes medicine canagliflozin". U.S. Food and Drug Administration (FDA). 26 August 2020. Retrieved 28 August 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  8. ↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 687. ISBN   9780857113382.
  9. ↑ Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. (December 2018). "Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetes Care. 41 (12): 2669–2701. doi:10.2337/dci18-0033. PMC   6245208 . PMID   30291106. patients with clinical CVD not meeting individualized glycemic targets while treated with metformin (or in whom metformin is contraindicated or not tolerated) should have an SGLT2 inhibitor or GLP-1 receptor agonist with proven benefit for cardiovascular risk reduction added
  10. ↑ Heston TF, Olson AH, Randall NR (December 2017). "Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not". Annals of Translational Medicine. 5 (23): 473. doi: 10.21037/atm.2017.09.28 . PMC   5733311 . PMID   29285506.
  11. ↑ "Summary Review" (PDF). U.S. Food and Drug Administration (FDA). 29 March 2013. Retrieved 9 July 2014.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  12. 1 2 "Invokana- canagliflozin tablet, film coated". DailyMed . 21 August 2020. Retrieved 28 August 2020.
  13. ↑ Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. (March 2018). "Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis". European Journal of Preventive Cardiology. 25 (5): 495–502. doi: 10.1177/2047487318755531 . PMID   29372664. S2CID   3557967.
  14. ↑ Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. (January 2019). "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials". Lancet. 393 (10166): 31–39. doi:10.1016/S0140-6736(18)32590-X. PMID   30424892. S2CID   53277899.
  15. ↑ Canagliflozin. Lexi-Drugs. Lexicomp Online [database online]. Hudson, OH: Lexicomp, Inc.  http://online.lexi.com . Updated 8 April 2017. Accessed 13 April 2017.
  16. ↑ Canagliflozin. Lexi-Drugs. Lexicomp Online [database online]. Hudson, OH: Lexicomp, Inc.  http://online.lexi.com . Updated 31 March 2017. Accessed 5 April 2017.
  17. ↑ Haberfeld, H (ed.). Austria-Codex (in German) (2013/14, supplement 01/14 ed.). Vienna: Österreichischer Apothekerverlag.
  18. ↑ "FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 29 August 2018.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  19. ↑ "SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood". U.S. Food and Drug Administration (FDA). 15 May 2015. Archived from the original on 27 October 2016. Retrieved 19 May 2015.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  20. 1 2 Tucker M (10 January 2013). "FDA Advisory Panel Supports Diabetes Drug Canagliflozin". Medscape Family Medicine. Retrieved 3 August 2015. Safety discussions by the panel circled back repeatedly to the cardiovascular risk data
  21. ↑ "FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood". U.S. Food and Drug Administration (FDA). 15 May 2015. Archived from the original on 22 July 2017. Retrieved 7 June 2016.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  22. ↑ "FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density". U.S. Food and Drug Administration (FDA). 10 September 2015. Retrieved 10 September 2015.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  23. ↑ "SGLT2 Inhibitors: Drug Safety Communication - Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections". U.S. Food and Drug Administration (FDA). 4 December 2015. Archived from the original on 16 March 2016. Retrieved 11 March 2016.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  24. ↑ "FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)". U.S. Food and Drug Administration (FDA). 14 June 2016. Retrieved 28 August 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  25. ↑ Schroeder C. "New Report Warns of Increasing SGLT2 & Invokana Risks". DrugNews. Pro Media One. Retrieved 8 August 2016.
  26. ↑ "FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate". U.S. Food and Drug Administration (FDA). 18 May 2016. Retrieved 28 August 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  27. ↑ "Press Release: FDA Confirms Increased Risk of Leg and Foot Amputations With Diabetes Medicine Canagliflozin". Fox Business. 16 May 2017. Retrieved 16 May 2017.
  28. ↑ "FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)". U.S. Food and Drug Administration (FDA). 16 May 2017. Retrieved 16 May 2017.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  29. 1 2 "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration (FDA). 19 March 2020. Retrieved 6 June 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  30. ↑ Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al. (August 2014). "Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy". American Journal of Nephrology. 40 (1): 64–74. doi: 10.1159/000364909 . PMID   25059406.
  31. ↑ Balis DA, Tong C, Meininger G (July 2014). "Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol". Journal of Diabetes. 6 (4): 378–380. doi: 10.1111/1753-0407.12116 . PMID   24330128. S2CID   36348840.
  32. ↑ Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, et al. (April 2020). "Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling". CPT. 9 (4): 222–229. doi:10.1002/psp4.12498. PMC   7180004 . PMID   32064793.
  33. ↑ Koufakis T, Mustafa OG, Tsimihodimos V, Ajjan RA, Kotsa K (August 2021). "Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?". Drugs. 81 (12): 1365–1371. doi:10.1007/s40265-021-01559-1. PMC   8261816 . PMID   34232488.
  34. ↑ "Integrity - Clarivate".
  35. ↑ Klement A (20 January 2014). "Tubuläre Senkung des Blutzuckers bei Diabetes mellitus: Invokana". Österreichische Apothekerzeitung (in German) (2/2014): 20f.
  36. ↑ Drugs.com: Canagliflozin Monograph .
  37. ↑ "First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease". Archived from the original on 13 March 2013. Retrieved 21 February 2013.
  38. ↑ "EMEA-001030-PIP01-10". EMA European Medicines Agency. Retrieved 6 May 2013.
  39. ↑ "U.S. FDA approves Johnson & Johnson diabetes drug, canagliflozin". Reuters. 29 March 2013. Archived from the original on 24 September 2015. Retrieved 30 June 2017. U.S. health regulators have approved a new diabetes drug from Johnson & Johnson, making it the first in its class to be approved in the United States.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.